mybbp1a Antibody

What is MYBBP1A and why is it important in research?

MYBBP1A was originally identified as a c-myb proto-oncogene product (c-Myb)-interacting protein. It is a 160-kDa protein (p160 MBP) that can be post-translationally processed to generate smaller fragments, including a 67-kDa N-terminal fragment (p67 MBP) . MYBBP1A is predominantly localized in the nucleolus but can translocate to the nucleoplasm under certain stress conditions. It plays critical roles in:

• Regulation of RNA polymerase I transcription and pre-rRNA processing

• p53 activation and tumor suppression in certain cancers

• Repression of transcription factors including PER2 in circadian rhythm regulation

• Control of cellular proliferation and stress response

What applications can MYBBP1A antibodies be used for?

MYBBP1A antibodies have been validated for multiple experimental applications:

Note: Optimal dilutions are antibody-specific and should be determined experimentally for each application .

How do I select the appropriate MYBBP1A antibody for my research?

When selecting a MYBBP1A antibody, consider:

• Epitope recognition: Some antibodies target specific domains of MYBBP1A. For example, some polyclonal antibodies are raised against synthetic peptides corresponding to amino acids 1265-1328 of human MYBBP1A .

• Species reactivity: Verify that the antibody recognizes MYBBP1A in your experimental species. Most commercial antibodies react with human MYBBP1A, while some also cross-react with mouse .

• Application compatibility: Ensure the antibody is validated for your specific application (WB, IHC, IF, etc.).

• Clonality: Monoclonal antibodies (like EPR7205) offer high specificity, while polyclonal antibodies may provide stronger signals but with potential for cross-reactivity .

• Validation data: Review published data or validation information from manufacturers showing antibody performance in applications similar to yours .

What are the optimal conditions for immunohistochemistry with MYBBP1A antibodies?

For successful immunohistochemical detection of MYBBP1A:

• Antigen retrieval: Heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 is recommended for many MYBBP1A antibodies. Alternatively, citrate buffer pH 6.0 may be used .

• Antibody dilution: Start with a 1:20-1:200 dilution range and optimize based on signal-to-noise ratio.

• Detection system: Use avidin-biotin-peroxidase complexes like Histofine SAB-PO Immunohistochemical Staining Kit for sensitive detection .

• Controls: Include positive controls (tissues known to express MYBBP1A) and negative controls (omitting primary antibody or using isotype control).

• Fixation: Formalin-fixed, paraffin-embedded tissues have been successfully used for MYBBP1A detection .

Example protocol:

• Dewax tissue sections in xylene and rehydrate in alcohol

• Perform heat-mediated antigen retrieval using EDTA buffer (1 mM, pH 8.0) in a microwave for 5 minutes

• Block endogenous peroxidase activity with 3% hydrogen peroxide in methanol for 6 minutes

• Apply MYBBP1A antibody at optimized dilution and incubate overnight at 4°C

• Use appropriate secondary antibody detection system

• Counterstain, dehydrate, and mount

How should I optimize Western blot analysis for MYBBP1A detection?

MYBBP1A appears as a 150-160 kDa band in Western blots. To optimize detection:

• Sample preparation: Nuclear or nucleolar extracts are recommended since MYBBP1A is predominantly nucleolar. Whole cell lysates may also be used depending on expression levels.

• Protein loading: 20-40 μg of total protein is typically sufficient for detection from cell lines expressing endogenous levels of MYBBP1A.

• Antibody dilution: Begin with 1:2000-1:10000 dilution and adjust based on signal strength.

• Expected bands:

  • Full-length MYBBP1A: 150-160 kDa

  • Processed forms: p140 MBP, p67 MBP (~67 kDa)

• Controls: Include positive control lysates (HeLa or HEK-293 cells) .

What considerations are important for immunofluorescence using MYBBP1A antibodies?

For optimal immunofluorescence results:

• Fixation and permeabilization:

  • Option 1: 4% paraformaldehyde fixation (15 min) followed by 0.25% Triton X-100 permeabilization

  • Option 2: Ice-cold methanol/acetone (1:1) fixation for 1 minute

• Blocking: PBS-Tween 0.01% containing 2% BSA and 5% goat serum for 1 hour .

• Antibody dilution: 1:20-1:200 for primary antibody, with overnight incubation at 4°C recommended for weaker signals.

• Expected localization: MYBBP1A typically shows strong nucleolar staining with weaker nucleoplasmic signal. Under stress conditions (ActD treatment, UV, etc.), expect translocation to the nucleoplasm .

• Counterstaining: DAPI for nuclear visualization, and consider co-staining with nucleolar markers like nucleolin or fibrillarin to confirm nucleolar localization.

How can MYBBP1A antibodies be used to study nucleolar-nucleoplasmic translocation?

MYBBP1A translocation from nucleolus to nucleoplasm occurs during cellular stress and is critical for its role in p53 activation. To study this:

• Stress induction methods:

  • Actinomycin D (ActD): Low doses inhibit RNA polymerase I

  • UV irradiation: Induces nucleolar stress

  • Cisplatin: Disrupts ribosome biogenesis

• Immunofluorescence protocol:

  • Treat cells with stress inducer (e.g., ActD at 5 nM for 4 hours)

  • Fix and perform immunofluorescence as described above

  • Co-stain with nucleolar markers to assess nucleolar integrity

  • Quantify nucleolar vs. nucleoplasmic signal intensities

• Subcellular fractionation:

  • Isolate nucleolar, nucleoplasmic, and cytoplasmic fractions

  • Perform Western blotting with MYBBP1A antibody

  • Quantify distribution changes between fractions after stress treatment

• Live-cell imaging:

  • Create GFP-MYBBP1A fusion constructs

  • Validate localization using antibodies

  • Monitor real-time translocation upon stress induction

What methods are recommended for studying MYBBP1A interactions with p53?

MYBBP1A enhances p53 target gene transcription and stabilizes p53 dimers. To investigate this interaction:

• Co-immunoprecipitation (Co-IP):

  • Lyse cells in TNE buffer (150 mM NaCl, 0.5% Nonidet P-40, 50 mM Tris-HCl, pH 8.0, 5 mM EDTA)

  • Immunoprecipitate with anti-MYBBP1A or anti-p53 antibodies

  • Analyze by immunoblotting with antibodies against the interacting partner

  • Include acetylation-specific antibodies (e.g., p53-K382Ac) to assess p53 activation status

• Sequential Co-IP for complex analysis:

  • Use differentially tagged proteins (FLAG, HA, Myc) for sequential pull-downs

  • This approach has revealed that MYBBP1A can bind to p53 dimers via two distinct binding domains

• GST pulldown assays:

  • Express GST-tagged MYBBP1A domains

  • Incubate with in vitro translated p53

  • Analyze binding in TNE buffer to map interaction domains

• Chromatin immunoprecipitation (ChIP):

  • Assess p53 recruitment to target promoters (e.g., BAX) with and without MYBBP1A

  • Compare occupancy under normal vs. stress conditions (e.g., detached growth to induce anoikis)

How can MYBBP1A antibodies be used to investigate its role in cancer progression?

MYBBP1A exhibits context-dependent roles in cancer - suppressing tumorigenesis in breast cancer but potentially promoting progression in hepatocellular carcinoma (HCC):

• Tissue microarray analysis:

  • Use IHC with MYBBP1A antibodies on cancer tissue microarrays

  • Score expression levels (e.g., 0-4 scale based on percentage of positive cells)

  • Correlate with clinical parameters and survival data

• RNA-protein correlation:

  • Combine IHC data with transcriptomic analysis

  • Assess correlation between MYBBP1A protein levels and expression of target genes

  • Example: In HCC, MYBBP1A protein levels correlate with IGFBP4/IGFBP5 suppression through methylation

• Functional studies after manipulation:

  • Create knockdown or overexpression cell models

  • Assess effects on:

    • Colony formation

    • Xenograft tumor growth

    • Anoikis resistance

    • Migration and invasion

  • Use MYBBP1A antibodies to confirm modification of protein levels

What approaches can be used to study MYBBP1A's role in ribosomal RNA processing?

MYBBP1A regulates both rRNA gene transcription and pre-rRNA processing:

• Nucleolar isolation and analysis:

  • Isolate nucleoli using established protocols

  • Confirm MYBBP1A presence by immunoblotting

  • Analyze associated ribosomal proteins and processing factors

• RNA Immunoprecipitation (RIP):

  • Use MYBBP1A antibodies to pull down associated RNA species

  • Analyze pre-rRNAs and processing intermediates by RT-qPCR or Northern blotting

• RNA processing analysis:

  • Manipulate MYBBP1A levels (overexpression or knockdown)

  • Analyze rRNA processing intermediates by Northern blot

  • Quantify levels of 47/45S, 41S, 30S, and 21S pre-rRNAs

  • MYBBP1A overexpression has been shown to affect mainly pathway A of rRNA processing

• Combined ChIP-seq and RNA-seq:

  • Map MYBBP1A binding sites on rDNA

  • Correlate with transcriptional changes and processing defects

What are common issues when using MYBBP1A antibodies and how can they be resolved?

How can I address contradictory findings regarding MYBBP1A's role in different cancer types?

Research suggests context-dependent roles for MYBBP1A in cancer progression:

• Experimental design considerations:

  • Cell type specificity: MYBBP1A functions as a tumor suppressor in breast cancer but may promote progression in hepatocellular carcinoma .

  • p53 status matters: MYBBP1A's tumor-suppressive function is observed primarily in p53 wild-type cells .

  • Subcellular localization: Assess nucleolar vs. nucleoplasmic distribution in different cancers.

  • Post-translational processing: Examine the ratio of p160 to p67 forms in different contexts .

• Analytical approaches:

  • Comprehensive pathway analysis: In breast cancer, MYBBP1A enhances p53-dependent anoikis , while in HCC it regulates the IGF1/AKT pathway through IGFBP5 methylation .

  • Temporal considerations: In head and neck squamous cell carcinoma, MYBBP1A promotes proliferation in early phases but suppresses migration and invasion in advanced tumors .

  • Integration with clinical data: The human protein atlas shows MYBBP1A as a favorable prognostic marker in pancreatic cancer but unfavorable in renal cancer, thyroid cancer, and melanoma .

• Resolution strategies:

  • Cell-specific knockout/knockin models

  • Domain-specific mutations to dissect functional differences

  • Multi-cancer tissue microarray analysis with standardized antibodies and scoring

What controls are essential when using MYBBP1A antibodies in different applications?

• Western blot controls:

  • Positive control lysates: HeLa or HEK-293 cells are recommended

  • MYBBP1A knockdown/knockout lysates to confirm antibody specificity

  • Loading controls: preferably nuclear proteins like Lamin B1

• IHC controls:

  • Positive tissue controls: Tissues known to express MYBBP1A

  • Negative controls: Omission of primary antibody or use of isotype control

  • Peptide competition: Pre-incubation of antibody with immunizing peptide should abolish specific staining

• Immunofluorescence controls:

  • Secondary antibody only: Check for non-specific binding

  • RNase treatment: MYBBP1A localization can be RNA-dependent

  • Negative controls described in product documentation:

    • Primary antibody with mismatched secondary

    • Secondary antibody with mismatched primary

• RNA stress response controls:

  • ActD treatment (5 nM): Should cause nucleolar-to-nucleoplasmic translocation

  • Other RNA Pol I inhibitors as positive controls for stress response

What emerging methodologies can enhance MYBBP1A research using antibodies?

Several cutting-edge approaches can advance MYBBP1A research:

• Proximity labeling techniques:

  • BioID or TurboID fused to MYBBP1A to identify proximal interacting partners under different conditions

  • APEX2-based labeling to capture transient interactions

  • Validation of identified interactors using co-IP with MYBBP1A antibodies

• Live-cell imaging with antibody fragments:

  • Development of Fab fragments or nanobodies against MYBBP1A

  • Conjugation with cell-permeable fluorophores

  • Real-time tracking of endogenous MYBBP1A translocation

• Super-resolution microscopy:

  • Using primary MYBBP1A antibodies with super-resolution compatible fluorophores

  • Studying sub-nucleolar localization and dynamics

  • Co-localization with processing factors at nanometer resolution

• Spatial transcriptomics:

  • Combining MYBBP1A immunofluorescence with in situ RNA sequencing

  • Correlating MYBBP1A localization with local transcriptional activity

  • Understanding spatial regulation of target genes

How can MYBBP1A antibodies contribute to understanding its role in therapeutic applications?

As a regulator of p53 and other critical cellular processes, MYBBP1A represents a potential therapeutic target:

• Biomarker development:

  • Standardized IHC protocols using validated MYBBP1A antibodies for patient stratification

  • Correlation of MYBBP1A levels with treatment response in different cancers

  • Investigation of MYBBP1A phosphorylation or other modifications as response indicators

• Target validation studies:

  • ChIP-seq using MYBBP1A antibodies to identify genome-wide binding sites

  • Assessment of MYBBP1A in drug response pathways

  • Studying MYBBP1A-dependent sensitization to chemotherapeutics

• Drug development applications:

  • Screening for compounds that modulate MYBBP1A-p53 interactions

  • Development of assays using MYBBP1A antibodies to monitor drug effects on localization

  • Evaluation of MYBBP1A in combination therapy approaches

• Antibody-based therapeutics:

  • Investigation of intrabodies targeting specific MYBBP1A domains

  • Exploring antibody-drug conjugates for targeting MYBBP1A-overexpressing cancer cells

  • Development of degraders that could be monitored using existing antibodies